Vanda Pharmaceuticals Inc., a prominent player in the biotechnology sector, has recently disclosed significant ownership information through a Schedule 13G/A filing with the U.S. Securities and Exchange Commission (SEC). This filing, dated October 9, 2026, reveals that entities and individuals associated with Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander collectively hold approximately seven percent of Vanda Pharmaceuticals’ common stock.
The filing is in compliance with Rule 13d‑1(k), indicating that the ownership stake is not intended to influence control over the company. This disclosure is part of the regulatory requirements for significant shareholders and is accompanied by a joint filing agreement. The agreement, signed by the involved parties, confirms that the disclosures are made jointly and adhere to the applicable SEC rules.
Vanda Pharmaceuticals Inc. operates within the health care sector, focusing on the development and commercialization of clinical-stage small molecule product candidates aimed at treating central nervous system disorders. The company is listed on the Nasdaq exchange and trades in USD. As of October 8, 2026, the close price of Vanda Pharmaceuticals’ stock was $4.57. The company’s market capitalization stands at approximately $273.9 million.
Over the past year, the stock has experienced fluctuations, with a 52-week high of $9.94 recorded on March 9, 2026, and a 52-week low of $4.27 on November 6, 2025. The price-to-earnings ratio is currently at -0.97, reflecting the company’s financial performance and market valuation.
This ownership disclosure does not indicate any additional corporate actions or changes in financial metrics. Vanda Pharmaceuticals continues its focus on advancing its product pipeline and contributing to the biopharmaceutical landscape, particularly in the realm of central nervous system disorders.
